Executive summary
Eli Lilly launched discounted versions of its obesity drug Zepbound, with starter doses in vials costing up to $549 a month. This was lauded as an innovative solution that expands supply and access, praised by patient groups and even President Biden.
However, a closer look at the announcement suggests the new offering may not expand access as much as claimed. Lilly's discounted versions are designed for starter doses only, leaving unclear how many patients will actually benefit from the change.
Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats
Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug Zepbound. Before, the treatment had only been sold in injectable pens for a list price of $1,060 per month, but now, Lilly will also sell starter doses in vials that cost up to $549 a month, “expanding supply and access,” the company said.
In Lilly’s press release, one patient group called it “an innovative solution that brings us closer to making equitable care a reality.” And even President Biden chimed in on X, crediting his administration’s work on pressuring drugmakers to lower prices.
But a deeper look at the announcement suggests the new offering may not expand access as much as the company indicates.
STAT+ Exclusive Story
Already have an account? Log in
Get unlimited access to award-winning journalism and exclusive events.
